Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher T Chen

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Nature Communications|February 7, 2026
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategiesTadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
Research Square|November 24, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesTadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
Cancer Research Communications|August 23, 2024
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid TumorsChristopher T Chen, Vishesh Khanna, Shivaani Kummar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 5, 2024
NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024Reid M Ness, Xavier Llor, Mohammad Ali Abbass, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Nature Communications|February 7, 2026
Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategiesTadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
Research Square|November 24, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesTadashi Manabe, Hannah C Bergo, Qingtian Li, et al.
Cancer Research Communications|August 23, 2024
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid TumorsChristopher T Chen, Vishesh Khanna, Shivaani Kummar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 5, 2024
NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024Reid M Ness, Xavier Llor, Mohammad Ali Abbass, et al.
Pageof 4